Bio-Techne rises nearly 4% as investors position ahead of May 6 earnings
Bio-Techne shares are higher as investors position ahead of the company’s next earnings report, expected May 6, 2026, and lean into a rebound after recent volatility. The last reported quarter (ended Dec. 31, 2025) delivered adjusted EPS of $0.46 on $295.9 million of revenue, supporting renewed buying interest.
1. What’s moving the stock
Bio-Techne (TECH) is up about 3.8% in the latest session as traders rotate into life-science tools names and position for the company’s next earnings report, which is widely expected on May 6, 2026. With no fresh company press release surfacing in the most recent checks, the price action looks driven by anticipatory buying and a bounce after recent large swings in the stock.
2. The most recent fundamentals investors are anchoring to
The most recent reported results (fiscal second quarter, ended December 31, 2025) showed revenue of $295.9 million with flat reported and organic growth versus the prior year, while profitability improved on an adjusted basis. Bio-Techne reported GAAP EPS of $0.24 and adjusted EPS of $0.46, alongside a 31.1% adjusted operating margin, as productivity and cost containment initiatives contributed to margin expansion.
3. What to watch next
With the next earnings date approaching, investors will focus on whether Bio-Techne can extend momentum in large pharma demand and sustain margins, while monitoring Diagnostics and Spatial Biology trends after prior softness. Short interest has been elevated (about 9% of shares outstanding in recent data), which can add fuel to short-covering on up days but also increase downside volatility if expectations reset.